Search Results
Apr 22, 2026, 07:00 ET Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
paclitaxel, with or without bevacizumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), the trial's primary endpoint, and overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer whose
More news about: Labcorp
Apr 22, 2026, 07:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
could lead to improved patient outcomes."The featured Genprex-supported abstract at ASCO 2026:Title: "Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid"Abstract Number: e15184About Reqorsa® Gene TherapyREQORSA® Gene
More news about: Genprex, Inc.
Apr 21, 2026, 18:50 ET /U P D A T E -- Nuvation Bio Inc./
49.7 months, a median PFS of 46.1 months and an intracranial response rate of 76.5% in patients with brain metastases (n=17). Median OS was not yet reached.For TKI-pretreated patients (n=113): the analysis showed a cORR of 55.8%, a median DOR of 16.6 months, a median PFS of 9.7 months and an
More news about: Nuvation Bio Inc.
Apr 21, 2026, 16:05 ET Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
response exceeding 6 months. Responses were observed irrespective of RAS/RAF mutation status.Progression-Free Survival (PFS): The median PFS for the evaluable population was 5.5 months. Notably, 42% of patients remained progression-free at the 6-month landmark, with 9 patients remaining
More news about: Inhibrx Biosciences, Inc.
Apr 21, 2026, 16:05 ET Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
untreated HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA), including a rapid oral presentation of analyses of progression-free survival (PFS) and overall survival (OS) across PD-L1 subgroups, as well as analyses of the characterization and management of gastrointestinal adverse events.Analyses
More news about: Jazz Pharmaceuticals plc
Apr 21, 2026, 12:45 ET Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026
announced that the study had met its primary endpoint with statistically significant and clinically meaningful improvement in progression-free survival (PFS).Updated clinical data of DZD6008 in pretreated NSCLC patients with EGFR C797X mutations have also been selected for oral presentation. DZD6008
More news about: Dizal Pharmaceutical
Apr 21, 2026, 07:00 ET Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
three patients out of the twelve originally enrolled in the Phase 1 dose escalation portion of the study who had prolonged progression-free survival (PFS). One patient attained a partial remission after the second course of REQORSA and Tagrisso and has maintained this response through 60 courses of treatment
More news about: Genprex, Inc.
Apr 20, 2026, 22:54 ET Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
continued to deliver robust and durable survival benefits. Results were particularly strong in patients with locally advanced disease, where the median PFS reached 11.1 months and the median OS exceeded 23 months. Landmark survival rates in this group included a 12-month OS rate of 91.7% and a 24-month OS
More news about: Akeso, Inc.
Apr 20, 2026, 17:03 ET Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Ratio [HR] 0.479; 95% CI: 0.33, 0.68); P<0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo. Importantly, ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic
More news about: Inhibrx Biosciences, Inc.
Apr 20, 2026, 08:05 ET Accord BioPharma's IMULDOSA® (ustekinumab-srlf) Now Preferred Under Cigna Healthcare Commercial Plans
Prefilled syringes (PFS) preferred on pharmacy benefit; vials preferred on medical benefitRALEIGH, N.C., April 20, 2026 /PRNewswire/ --
More news about: Accord BioPharma
Apr 20, 2026, 02:30 ET New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore
maintenance treatment option over AT alone in patients with this aggressive cancer, with improvements recorded in both median progression free survival (PFS; 5.4 months vs. 2.1 months) and median overall survival (OS; 13.2 months vs.10.6 months).[13]Significant variations in treatment-related
More news about: Specialised Therapeutics
Apr 17, 2026, 09:30 ET Funded Builders Are Pulling Away From the Gold Mining Pack
independent of the Company. Cautionary Note on Production Decision:Although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: Equity Insider
Apr 16, 2026, 21:05 ET MAYFAIR COMPLETES PRIVATE PLACEMENT WITH KEVIN ANNETT
company focused on advancing the 100% controlled Fenn-Gib Project in the Timmins region of Northern Ontario. The Project's pre-feasibility study (the "PFS") outlines the potential to develop Fenn-Gib into a new Canadian gold producer for initial development capital of C$450 million, with a base case
More news about: Mayfair Gold Corp.
Apr 16, 2026, 07:00 ET Defense Metals Announces Inclusion in New Sprott Rare Earths Ex-China ETF
reserve, as detailed in the Company's 2025 Pre Feasibility Study ("PFS") (refer to Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects. The PFS, showed the economic potential of the deposit, supporting future
More news about: Defense Metals Corp.
Apr 15, 2026, 09:44 ET America's Largest Conventional Uranium Deposit Just Broke Ground on a Production Roadmap
optimized the 47-hole, 27,000-foot footprint to address the specific data gaps standing between Aurora and a PFS-grade resource model. The objective isn't a sprawling scout campaign — it's a focused, PFS-targeted exercise scheduled to begin in July, with a financial position to match: Eagle reported $31.3
More news about: USA News Group
Apr 15, 2026, 07:00 ET Grounded Lithium Reports 2025 Year End Results and Oil and Gas Operations Update
completion and filing of a pre-feasibility study ("PFS"). The PFS will incorporate detailed operational, technical and financial assessments for the KLP. The combined expertise from Denison and GLC will support a meticulous approach to the PFS that acknowledges all the necessary engineering aspects
More news about: Grounded Lithium Corp.
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
therapy. The median follow-up was 22.2 months (data cutoff date: November 17, 2025).The data showed that median progression-free survival (PFS) in the overall population was 20.9 months; median overall survival (OS) was not reached; and the 12-month OS rate was 92%. Additionally,
More news about: Kelun-Biotech
Apr 13, 2026, 07:00 ET UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
studies assessed the bioequivalence and effectiveness of zilucoplan auto-injector (ZLP-AI) administration compared with pre-filled syringe (ZLP-PFS)1UCB is presenting 21 abstracts in total from its innovative neurology portfolio including 14 epilepsy abstracts and six myasthenia gravis
More news about: UCB
Apr 13, 2026, 06:45 ET Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
daily) plus venetoclax and rituximab per their labeled doses or venetoclax and rituximab alone. The primary endpoint is PFS as assessed by blinded IRC. Secondary endpoints include PFS as assessed by investigator, OS, time to next treatment, event-free survival, overall response rate, time to worsening
More news about: Eli Lilly and Company
Apr 13, 2026, 06:00 ET IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
clinically meaningful benefit in PFS in the clinical setting of first-line HLA-A*02:01-negative metastatic uveal melanoma. For patients with uveal melanoma, these results potentially offer a new treatment option that delivers a significant clinical advancement in both PFS and ORR versus currently available
More news about: IDEAYA Biosciences, Inc.
Apr 12, 2026, 07:15 ET AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
after six cycles in the overall population (FRα ≥25%) and additional secondary endpoints included duration of response (DoR), progression-free survival (PFS) and overall survival (OS). "Despite being considered chemotherapy-responsive, platinum-sensitive ovarian cancer (PSOC) remains challenging to
More news about: AbbVie
Apr 10, 2026, 07:25 ET DualityBio gibt Annahme des Zulassungsantrags für Trastuzumab Pamirtecan zur Behandlung von nicht resezierbarem oder metastasiertem HER2-positivem Brustkrebs bei erwachsenen Patienten durch die chinesische NMPA bekannt
Studie bei einer vorab festgelegten Zwischenanalyse den primären Endpunkt einer statistisch signifikanten Verbesserung des progressionsfreien Überlebens (PFS; bewertet durch Blinded Independent Central Review, BICR) für Trastuzumab Pamirtecan im Vergleich mit T-DM1. Dr. Hua Mu, globaler medizinischer
More news about: DualityBio
Apr 10, 2026, 07:23 ET DualityBio annonce l'acceptation par la NMPA chinoise de la demande d'autorisation de mise sur le marché du trastuzumab pamirtecan pour le traitement du cancer du sein HER2 positif non résécable ou métastatique chez l'adulte
des données (IDMC), l'essai a atteint son objectif principal, à savoir une amélioration statistiquement significative de la survie sans progression (PFS, évaluée par l'examen central indépendant en aveugle, BICR) pour le trastuzumab pamirtecan par rapport au T-DM1, lors d'une analyse intermédiaire pré-spécifiée.
More news about: DualityBio
Apr 09, 2026, 09:03 ET Alpheus Medical Initiates Phase 2b Trial of Investigational Therapy for Newly Diagnosed Glioblastoma
radiochemotherapy. The study compares standard of care alone to standard of care plus investigational therapy. The primary endpoint is progression-free survival (PFS) with key secondary endpoints including overall survival (OS), safety, and tolerability.For patients and caregivers seeking more information
More news about: Alpheus Medical
Apr 09, 2026, 08:16 ET DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
Independent Data Monitoring Committee (IDMC), the trial has met its primary endpoint of statistically significant improvement of progression-free survival (PFS, assessed by Blinded Independent Central Review, BICR) for trastuzumab pamirtecan compared to T-DM1 at a pre-specified interim analysis. Dr.
More news about: DualityBio